Nursing care
Colchicine: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Colchicine treats the acute gout attack, and the nurse's job is to stop the dose at the first sign of diarrhoea, which signals early toxicity rather than a tolerable side effect. Dosing is reduced in renal impairment because the drug accumulates and the toxic-to-therapeutic margin is narrow.
Why this drug and not another
Colchicine works on the acute gout flare by blocking neutrophil migration into the joint, cutting the inflammatory cascade at its source rather than lowering uric acid. That makes it distinct from allopurinol or febuxostat, which manage long-term urate levels and have no role in an attack already underway.
It is reached for when NSAIDs are contraindicated, such as in a patient on warfarin or with active peptic ulcer disease, or when corticosteroids are unsuitable because of poorly controlled diabetes. Its narrow therapeutic index and heavy drug interaction profile mean it is rarely first-line when a safer option exists.
Administration and timing
For an acute attack, current dosing is low-dose and front-loaded: an initial dose followed by a smaller dose an hour later, then stopped, rather than continued round-the-clock. This replaced older high-dose regimens that caused unacceptable toxicity for barely better efficacy.
The critical instruction for the patient and the nurse alike is to stop at the first loose stool. Diarrhoea is not an incidental gut upset to push through, it is the earliest clinical sign that colchicine has reached a toxic level. Continuing the drug past that point risks progression to bone marrow suppression and multi-organ failure.
Renal impairment slows clearance, so the dose is reduced, and in significant renal failure the drug may be avoided altogether. Check renal function before the first dose and factor it into any repeat course within the following two weeks.
Monitoring parameters
Baseline and ongoing renal function guide dosing, since colchicine is renally cleared and impairment prolongs its half-life significantly. Hepatic function matters too, as the drug is also metabolised by the liver and impairment there compounds the accumulation risk.
Watch a full blood count for concurrent or recent therapy, because bone marrow suppression is the feared endpoint of colchicine toxicity and it can present as leukopenia, thrombocytopenia, or aplastic anaemia. Muscle symptoms and creatine kinase are worth checking in a patient on a statin or a CYP3A4 inhibitor, since colchicine-induced myopathy can progress to rhabdomyolysis in that combination.
Adverse effects to report
Gastrointestinal symptoms come first and matter most: nausea, vomiting, abdominal cramping, and diarrhoea are the earliest markers of toxicity, not a side effect to tolerate. Any of these means holding the next dose and notifying the prescriber immediately rather than waiting for the next scheduled dose.
Beyond the gut, report unexplained bruising or bleeding, sore throat or fever, and muscle weakness or dark urine, all of which point toward bone marrow suppression or rhabdomyolysis. Peripheral numbness or tingling can signal peripheral neuropathy with prolonged or repeated courses.
Contraindications and cautions
Severe renal or hepatic impairment, particularly when both are affected together, is a contraindication because clearance of the drug collapses and toxicity becomes near-certain at standard doses. Concurrent use with strong CYP3A4 or P-glycoprotein inhibitors, such as clarithromycin or certain antifungals, is avoided or requires substantial dose reduction because these combinations have caused fatal toxicity.
Pregnancy and breastfeeding require a risk-benefit discussion with the prescriber, and a history of blood dyscrasias warrants particular caution given the bone marrow suppression risk.
Teaching points the exam tests
NCLEX-style questions on colchicine reliably hinge on one distinction: diarrhoea is not a nuisance side effect to manage symptomatically, it is the signal to stop the drug and call the prescriber. A question that offers antidiarrheal treatment as the correct next step is testing whether you missed that.
Expect questions pairing colchicine with renal function results, expecting you to recognise that a rising creatinine or reduced eGFR should prompt dose reduction or a call to the prescriber before the next dose is given. Interaction questions involving grapefruit juice, clarithromycin, or statins are also common, testing recognition of CYP3A4-related toxicity risk.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Why do you stop colchicine as soon as diarrhoea starts?
Diarrhoea is the earliest clinical sign of colchicine toxicity, appearing before the more dangerous effects on bone marrow and muscle develop. Continuing the drug past this point increases the risk of progressing to bone marrow suppression, which can be fatal, so the standard response is to hold the dose and contact the prescriber.
Does colchicine dose change with kidney disease?
Yes. Colchicine is cleared renally, so impaired kidney function slows elimination and raises blood levels, meaning the dose is reduced accordingly. In significant renal impairment the drug may need to be avoided entirely, and repeat courses within a short window are approached with extra caution.
Can colchicine be used to prevent gout attacks, not just treat them?
Yes, low-dose colchicine is sometimes used prophylactically, particularly when starting urate-lowering therapy such as allopurinol, since initiating that treatment can trigger a flare. This is a lower, steadier dose than the acute-attack regimen and still carries the same toxicity considerations.
What drug interactions matter most with colchicine?
Strong CYP3A4 or P-glycoprotein inhibitors, including clarithromycin, certain antifungals, and some HIV protease inhibitors, can raise colchicine levels sharply and have caused fatal toxicity in combination. Statins also warrant caution because of an increased risk of myopathy when combined with colchicine.
More on pharmacology
Guides on this